Orencia Related Published Studies
Well-designed clinical trials related to Orencia (Abatacept)
Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. [2009.04]
Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. [2008.11]
Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. [2008.08.01]
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. [2008.08]
Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. [2008.07]
Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the Abatacept in Inadequate Responders to Methotrexate (AIM) trial. [2008.04]
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. [2008.04]
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. [2008.04]
Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. [2008.02]
Responsiveness of patient reported outcomes including fatigue, sleep quality and activity limitation and quality of life following treatment with abatacept in patients with rheumatoid arthritis. [2007.09.25]
Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. [2007.02]
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. [2007.02]
Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. [2006.11]
Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. [2006.10]
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. [2006.09]
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. [2006.06.20]
Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. [2006.04]
Abatacept. [2006]
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. [2005.09.15]
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. [2005.08]
Well-designed clinical trials possibly related to Orencia (Abatacept)
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. [2008.10]
The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study. [2008.05]
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2008.01]
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2007.06.15]
Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. [2007.06]
Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. [2007.05]
Human clinical trials in lupus nephritis. [2007.01]
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. [2003.11.13]
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. [2002.06]
Other research related to Orencia (Abatacept)
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. [2009.11]
Abatacept for rheumatoid arthritis. [2009.10.07]
Relative efficacies: antimalarials to abatacept - the choice is ours. [2009.06]
Abatacept therapy and safety management. [2009.05]
Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. [2009.04]
Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. [2009.04]
Investigating the validity of the minimal disease activity state for patients with rheumatoid arthritis treated with abatacept. [2009.02]
[Abatacept in the treatment of active rheumatoid arthritis] [2009.01.26]
[Abatacept in the treatment of active rheumatoid arthritis] [2009.01.19]
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. [2009.01.05]
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. [2009.01]
[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation] [2009]
Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept. [2009]
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. [2008.12.15]
Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. [2008.12.11]
Improving patient outlook in rheumatoid arthritis: experience with abatacept. [2008.10]
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. [2008.09]
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. [2008.08.02]
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. [2008.08]
Abatacept in biologic-naive patients and TNF inadequate responders: clinical data in focus. [2008.08]
Cost-Effectiveness of Abatacept in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Tumor Necrosis Factor-alpha Antagonists. [2008.07.15]
Selective Costimulation Modulation with Abatacept: A Look at Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis. [2008.06.06]
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. [2008.04]
Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis. [2008.03]
An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. [2008.03]
Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. [2008.01.18]
Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis. [2008.01]
The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept. [2008.01]
Abatacept in the treatment of rheumatoid arthritis. [2008]
Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. [2007.12]
Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. [2007.12]
Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. [2007.11]
Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. [2007.09]
Quality of life in patients with rheumatoid arthritis: does abatacept make a difference? [2007.09]
Efficacy results from pivotal clinical trials with abatacept. [2007.09]
Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. [2007.08]
[CTLA4-Ig (abatacept)] [2007.07]
Update on abatacept: a selective costimulation modulator for rheumatoid arthritis. [2007.07]
Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis. [2007.03]
A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis. [2007.03]
Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. [2007]
Drug Insight: abatacept for the treatment of rheumatoid arthritis. [2006.12]
Abatacept. [2006.11.01]
Role of abatacept in the management of rheumatoid arthritis. [2006.11]
Other possibly related research studies
Report of the first World Transplant Congress. [2007.03]
[Management for TNF failure] [2007.07]
T cell immunomodulation--the Holy Grail of therapeutic tolerance. [2007.08]
New therapies for treatment of rheumatoid arthritis. [2007.06.12]
Immunomodulation by costimulation blockade inhibits rejection of nerve allografts. [2007.06]
Immunosuppression on the horizon. [2007.01]
Tolerance in heart transplantation: the Holy Grail, or an attainable goal? [2007.01]
The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins. [2007.06.01]
Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. [2007.06]
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. [2007.05]
The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. [2007.05]
[Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis] [2007.04]
Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. [2007.04.15]
CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of Indoleamine-2,3-dioxygenase. [2007.03.15]
Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. [2007.03]
Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. [2007.05]
New drugs 07, part I. [2007.02]
Current topics in melanoma. [2007.03]
[Perspectives in clinical immunology] [2006.12]
Induction of regulatory cells and control of cellular but not vascular rejection by costimulation blockade in hamster-to-rat heart xenotransplantation. [2007.01]
Inhibiting costimulatory activation of T cells : a viable treatment option for rheumatoid arthritis? [2007]
IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice. [2006.12]
Enhancing engraftment of neonatal porcine xenoislet with CTLA4Ig and nordihydroguaiaretic acid. [2006.12]
Long-term survival of cardiac allografts induced by cyclophosphamide combined with CTLA4Ig-gene transfer mediated by adenoviral vector. [2006.11]
Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice. [2008.08]
[Biological treatment options for Graves' ophthalmopathy] [2008.06.09]
[Biological therapy treatment of juvenile idiopathic arthritis] [2008.06.09]
B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. [2008.04]
|
